[HTML][HTML] Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
JH van den Berg, B Heemskerk… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
JH van den Berg, B Heemskerk, N van Rooij, R Gomez-Eerland, S Michels, M van Zon…
Journal for immunotherapy of cancer, 2020•ncbi.nlm.nih.govAbstract Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes
(TILs) is currently applied in several centers. Robust and remarkably consistent overall
response rates, of around 50% of treated patients, have been observed across hospitals,
including a substantial fraction of durable, complete responses. Purpose Execute a phase I/II
feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute,
with the goal to assess feasibility and potential value of a randomized phase III trial.
(TILs) is currently applied in several centers. Robust and remarkably consistent overall
response rates, of around 50% of treated patients, have been observed across hospitals,
including a substantial fraction of durable, complete responses. Purpose Execute a phase I/II
feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute,
with the goal to assess feasibility and potential value of a randomized phase III trial.
Abstract
Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers. Robust and remarkably consistent overall response rates, of around 50% of treated patients, have been observed across hospitals, including a substantial fraction of durable, complete responses.
Purpose
Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.
ncbi.nlm.nih.gov